The inflammasome is a multi-protein complex that activates caspase-1, leading to the secretion of pro-inflammatory cytokines IL-1β and IL-18, as well as pyroptosis, a form of cell death induced by bacterial pathogens. Key components of the inflammasome include NLRP1, NLRP3, NLRC4, and the adaptor ASC, which link microbial and endogenous danger signals to caspase-1 activation. Dysregulated inflammasome activity is associated with various diseases, highlighting its role in immune responses and disease pathogenesis. The innate immune system recognizes conserved microbial structures called PAMPs through receptors like TLRs and NLRs. NLRs detect microbial molecules in the host cytosol, while TLRs sense PAMPs on the cell surface or within endosomes. The NLR family includes 23 human and 34 mouse members, with homologs present in plants and some animals but not in insects or worms. Most NLRs have a tripartite structure, with domains involved in protein interactions and PAMP detection. NLRP1, NLRP3, and NLRC4 are critical for inflammasome assembly. NLRP3 is activated by various microbial stimuli, including LPS, MDP, and double-stranded RNA, as well as endogenous molecules like urate crystals and ATP. The NLRC4 inflammasome is activated by cytosolic flagellin from bacteria such as Salmonella, Legionella, and Pseudomonas. NLRP1 is activated by MDP, and its activation involves conformational changes and binding of nucleotides. NLRP3 activation is often dependent on the P2X7 receptor and extracellular ATP, which can induce pore formation and translocate microbial molecules into the cytosol. The inflammasome plays a critical role in host defense against pathogens, including Legionella and Mycobacterium tuberculosis. It also contributes to inflammatory diseases such as gout, pseudogout, and Alzheimer's disease. Mutations in NLRP3 are linked to autoinflammatory disorders, and targeting the inflammasome with IL-1 receptor antagonists has shown therapeutic benefits in these conditions. Understanding the mechanisms of inflammasome activation, regulation, and function is crucial for developing therapeutic strategies. Current research focuses on elucidating the molecular pathways involved in inflammasome activation, identifying novel substrates of caspase-1, and understanding the role of the inflammasome in various diseases. Advances in this area may lead to new treatments for inflammatory and autoimmune disorders.The inflammasome is a multi-protein complex that activates caspase-1, leading to the secretion of pro-inflammatory cytokines IL-1β and IL-18, as well as pyroptosis, a form of cell death induced by bacterial pathogens. Key components of the inflammasome include NLRP1, NLRP3, NLRC4, and the adaptor ASC, which link microbial and endogenous danger signals to caspase-1 activation. Dysregulated inflammasome activity is associated with various diseases, highlighting its role in immune responses and disease pathogenesis. The innate immune system recognizes conserved microbial structures called PAMPs through receptors like TLRs and NLRs. NLRs detect microbial molecules in the host cytosol, while TLRs sense PAMPs on the cell surface or within endosomes. The NLR family includes 23 human and 34 mouse members, with homologs present in plants and some animals but not in insects or worms. Most NLRs have a tripartite structure, with domains involved in protein interactions and PAMP detection. NLRP1, NLRP3, and NLRC4 are critical for inflammasome assembly. NLRP3 is activated by various microbial stimuli, including LPS, MDP, and double-stranded RNA, as well as endogenous molecules like urate crystals and ATP. The NLRC4 inflammasome is activated by cytosolic flagellin from bacteria such as Salmonella, Legionella, and Pseudomonas. NLRP1 is activated by MDP, and its activation involves conformational changes and binding of nucleotides. NLRP3 activation is often dependent on the P2X7 receptor and extracellular ATP, which can induce pore formation and translocate microbial molecules into the cytosol. The inflammasome plays a critical role in host defense against pathogens, including Legionella and Mycobacterium tuberculosis. It also contributes to inflammatory diseases such as gout, pseudogout, and Alzheimer's disease. Mutations in NLRP3 are linked to autoinflammatory disorders, and targeting the inflammasome with IL-1 receptor antagonists has shown therapeutic benefits in these conditions. Understanding the mechanisms of inflammasome activation, regulation, and function is crucial for developing therapeutic strategies. Current research focuses on elucidating the molecular pathways involved in inflammasome activation, identifying novel substrates of caspase-1, and understanding the role of the inflammasome in various diseases. Advances in this area may lead to new treatments for inflammatory and autoimmune disorders.